4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$18.35 USD
-0.17 (-0.92%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $18.32 -0.03 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FDMT 18.35 -0.17(-0.92%)
Will FDMT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FDMT
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
Other News for FDMT
Buy Rating for 4D Molecular Therapeutics: Promising Future Based on Product Efficacy and Strategic Growth Prospects
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
4D Molecular Therapeutics to Present PRISM Trial Interim Data
RBC Capital Keeps Their Buy Rating on 4D Molecular Therapeutics (FDMT)
Analysts’ Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)